We are live on ! Find out more
EAM

Exome Asset Management Portfolio holdings

AUM $193M
1-Year Est. Return 208.51%
This Fund
S&P 500
This Quarter Est. Return
+11.92%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$148M
AUM Growth
+$35.6M
Cap. Flow
+$28.1M
Cap. Flow %
18.99%
Top 10 Hldgs %
35.62%
Holding
82
New
30
Increased
14
Reduced
8
Closed
23

Top Buys

Rank Stock Value
1
GPCR icon
Structure Therapeutics
GPCR
+$4.65M
2
ALGN icon
Align Technology
ALGN
+$4.41M
3
GERN icon
Geron
GERN
+$4.12M
4
GILD icon
Gilead Sciences
GILD
+$3.82M
5
SWTX
SpringWorks Therapeutics
SWTX
+$3.76M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$5.2M
2
CRBP icon
Corbus Pharmaceuticals
CRBP
+$3.84M
3
TVTX icon
Travere Therapeutics
TVTX
+$3.64M
4
ONC
BeOne Medicines Ltd
ONC
+$3.22M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$3.03M

Sector Composition

Rank Sector Weight
1 Healthcare 98.79%
2 Financials 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
YARW
51
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
$664K 0.45%
7,069
– –
SYRS
52
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$642K 0.43%
298,575
+139,400
+88% +$501K
ADAG
53
Adagene
ADAG
$248M
$583K 0.39%
262,625
+111,749
+74% +$294K
GOSS icon
54
Gossamer Bio
GOSS
$82.9M
$462K 0.31%
468,499
-659,200
-58% -$634K
APRE icon
55
Aprea Therapeutics
APRE
$7.68M
$377K 0.26%
137,174
– –
PROC
56
DELISTED
Procaps Group, S.A. Ordinary Shares
PROC
$280K 0.19%
126,901
– –
CYPH
57
Cypherpunk Technologies Inc
CYPH
$62.9M
$264K 0.18%
+102,631
New +$252K
PACB icon
58
Pacific Biosciences
PACB
$435M
$128K 0.09%
75,300
– –
ABCL icon
59
AbCellera Biologics
ABCL
$1.74B
– –
-514,900
Closed -$1.52M
ARVN icon
60
Arvinas
ARVN
$518M
– –
-82,400
Closed -$2.19M
ATEC icon
61
Alphatec Holdings
ATEC
$1.46B
– –
-162,100
Closed -$1.69M
AUTL
62
Autolus Therapeutics
AUTL
$397M
– –
-839,472
Closed -$2.92M
AVDL
63
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-209,092
Closed -$2.94M
BHVN icon
64
Biohaven
BHVN
$2.03B
– –
-57,800
Closed -$2.01M
CABA icon
65
Cabaletta Bio
CABA
$437M
– –
-300,200
Closed -$2.25M
CRBP icon
66
Corbus Pharmaceuticals
CRBP
$166M
– –
-84,790
Closed -$3.84M
DXCM icon
67
DexCom
DXCM
$31.5B
– –
-25,928
Closed -$2.94M
ELEV
68
DELISTED
Elevation Oncology
ELEV
– –
-369,322
Closed -$997K
FULC icon
69
Fulcrum Therapeutics
FULC
$273M
– –
-302,700
Closed -$1.88M
HLVX
70
DELISTED
HilleVax
HLVX
– –
-18,000
Closed -$260K
NBP
71
NovaBridge Biosciences American Depositary Shares
NBP
$185M
– –
-271,400
Closed -$453K
MASI
72
DELISTED
Masimo
MASI
– –
-19,800
Closed -$2.49M
MDGL icon
73
Madrigal Pharmaceuticals
MDGL
$10.8B
– –
-10,800
Closed -$3.03M
MRUS
74
DELISTED
Merus
MRUS
– –
-45,100
Closed -$2.67M
PMVP icon
75
PMV Pharmaceuticals
PMVP
$59.2M
– –
-358,400
Closed -$581K
1 2
3
4

Similar funds

WWC
Waypoint Wealth Counsel Atlanta, Georgia $193M AUM 30.17% 1-Year Est. Return
JHA
Jackson Hill Advisors Houston, Texas $193M AUM 4.94% 1-Year Est. Return
TDWM
Topel & Distasi Wealth Management Berkeley, California $193M AUM 12.07% 1-Year Est. Return
DF
Downshift Financial Boulder, Colorado $193M AUM
SCM
Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return
PA
Promethium Advisors Bethesda, Maryland $193M AUM 23.69% 1-Year Est. Return
SCPM
Sea Cliff Partners Management San Francisco, California $194M AUM 8.22% 1-Year Est. Return
CA
Carson Advisory Athens, Georgia $193M AUM 14.52% 1-Year Est. Return

Exome Asset Management's Q3 2024 Portfolio in Review

As of Q3 2024, Exome Asset Management held 82 positions worth $148M, up 32% from $112M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Exome Asset Management deployed $28.1M of net new capital in Q3 2024, opening 30 new positions and adding to 14 existing holdings. Its largest new stake was Structure Therapeutics: 120,165 shares worth $5.27M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was BeOne Medicines Ltd, an estimated $3.22M trimmed.

  • Exome Asset Management's largest Q3 2024 buy was Structure Therapeutics: 120,165 shares worth $5.27M.
  • Exome Asset Management added most to BridgeBio Pharma in Q3 2024, an estimated $3.47M increase.
  • Exome Asset Management's biggest Q3 2024 reduction was BeOne Medicines Ltd, cutting an estimated $3.22M.
  • Exome Asset Management fully exited Sarepta Therapeutics in Q3 2024, selling an estimated $5.2M.
  • Exome Asset Management's ten largest holdings make up 36% of its $148M portfolio in Q3 2024.
  • Exome Asset Management opened 30 new positions and closed 23 in Q3 2024.
  • Exome Asset Management's portfolio value rose 32% quarter-over-quarter to $148M.

Based on Exome Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.